Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 negative breast cancer.
Breast Cancer
DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Gemcitabine
Overall response rate, up to 6 months
Progression Free Survival, 1 year|Toxicity profile, 21 days|Overall Survival, 1 year|Quality of life assessment, Assessment every two cycles
Docetaxel plus gemcitabine is an active combination in the salvage treatment for metastatic breast cancer. Administered every two weeks, this combination has a favorable toxicity profile, and promising activity in \> 1st line treatment for metastatic breast cancer. Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone. This study will evaluate the addition of bevacizumab to a biweekly regimen of docetaxel and gemcitabine in the salvage therapy for metastatic breast cancer.